Due to the involvement of BTK in multiple immunological signaling pathways, there have been a host of inhibitors developed with different binding modes all targeting the kinase domain of BTK as a treatment option for B cell lymphomas and other BTK-reliant diseases. This evidence concerns the gene BTK and B-cell non-Hodgkin lymphoma.